HOW DOES AUTOIMMUNITY TO LA AND RO INITIATE AND SPREAD

被引:18
作者
GORDON, T
TOPFER, F
KEECH, C
REYNOLDS, P
CHEN, WS
RISCHMUELLER, M
MCCLUSKEY, J
机构
[1] Department of Clinical Immunology and Centre for Transfusion Medicine and Immunology, Flinders Medical Centre, Bedford Park, SA
基金
英国医学研究理事会;
关键词
LA(SS-B); RO(SS-A); AUTOIMMUNITY; AUTOANTIBODIES; EPITOPE MAPPING; IMMUNE TOLERANCE;
D O I
10.3109/08916939409007981
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Autoimmunity to La(SS-B) and Ro(SS-A) is a paradigm for understanding the normal mechanisms of B cell and T cell tolerance and development of autoimmunity to clinically important sequestered autoantigens. Epitope mapping experiments have indicated that the autoantibody response is largely self antigen-driven but have failed to elucidate why these particular autoantigens are selected. Abnormal trafficking of La or Po peptides in polarised epithelial cells and their presentation to autoreactive T cells, or selective release of ribonucleoproteins by injured epithelial cells, could explain the targeting of salivary and lacrimal epithelium in Sjogren's syndrome. There appears to be little, if any, immune tolerance to La in the T helper and B cell compartments. Both intra-and inter-molecular spreading of the autoimmune response have been observed for La. We present a model of recruited autoimmunity whereby capture and internalisation of La/Ro ribonucleoproteins by B cells and subsequent presentation of La or Po determinants to autoreactive T cells could lead to inter-molecular spreading of the response.
引用
收藏
页码:87 / 92
页数:6
相关论文
共 36 条
[1]  
Tan E.M., Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology, Adv Immunol, 44, pp. 93-151, (1989)
[2]  
Harley J.B., Scofield R.H., Reichlin M., Anti-Ro in Sjogren's syndrome and systemic lupus erythematosus, Rheumatic Disease Clinics of North America, 18, 2, pp. 337-358, (1992)
[3]  
Chan E.K.L., Andrade L.E.C., Antinuclear antibodies in Sjogren's syndrome, Rheumatic Disease Clinics of North America, 18, 3, pp. 551-570, (1992)
[4]  
Ben-Chetrit E., The molecular basis of the SSA/Ro antigens and the clinical significance of their autoantibodies, Brit J. Rheumatol, 32, pp. 396-402, (1993)
[5]  
McCaulifFe D.P., Sontheimer R.D., Molecular characterisation of the Ro/SS-A autoantigens, J Invest Dermatol, 100, pp. 73-79, (1993)
[6]  
Gottlieb E., Steitz J.A., Function of the mammalian La protein: evidence for its action in transcription termination by RNA polymerase III in vitro, EMBO J, 8, pp. 851-861, (1989)
[7]  
Bachmann M., Pfeifer K., Schroder H.-C., Muller E.G., Characterisation of the autoantigen La and a nucleic acid-dependent ATPase/dATPase with melting properties, Cell, 60, pp. 85-93, (1990)
[8]  
Mamula M.J., Silverman E.D., Laxer R.M., Bentur L., Isacovics B., Hardin J.A., Human monoclonal anti-La antibodies: the La protein resides on a subset of Ro particles, J Immunol, 143, pp. 2923-2928, (1989)
[9]  
Boire G., Craft J., Human Ro ribonucleoprotein particles: Characterisation of native structure and stable association with the La polypeptide, J Clin Invest, 85, pp. 1182-1190, (1990)
[10]  
Ben-Chetrit E., Chan E.K.L., Sullivan K.F., Tan E.M., A 52 kD protein is a novel component of the SS-A/Ro particle, J Exp Med, 167, pp. 1560-1571, (1988)